Drug intelligence / Profile preview

PD182

Development stage: Unknown
Modality: Antibody-Based Therapeutics

Overview

PD182 is a polyclonal anti-idiotype antibody generated through rabbit immunization against adalimumab F(ab’)2. Developed using an advanced proteogenomics approach and strategic enrichment workflow, PD182 exhibits high specificity and affinity for adalimumab, with significantly reduced off-target binding to human IgG compared to commercially available anti-idiotypes. This makes it a promising tool for pharmacokinetic applications, capable of distinguishing between blocking (type 1) and non-blocking (type 2) variants.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on PD182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD182.

Explore the full profile